Income Statement
INHIBIKASE THERAPEUTICS, INC.
IKT
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | 0.00 | 0.26 | 0.12 | 3.10 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | 0.26 | 0.12 | 3.10 |
|
Operating Expenses
|
53.35 | 28.59 | 20.35 | 18.25 | 17.87 |
|
Research & Development
|
29.79 | 17.21 | 13.62 | 12.03 | 11.36 |
|
Selling, General & Administrative
|
23.56 | 11.38 | 6.73 | 6.22 | 6.51 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-53.35 | -28.59 | -20.09 | -18.13 | -14.77 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | 0.02 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-0.05 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-48.26 | -27.52 | -19.03 | -18.05 | -14.79 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-53.35 | -28.59 | -20.09 | -18.13 | -14.77 |
|
Earnings Per Share (Basic)
|
-0.49 | -1.16 | -3.57 | -0.72 | - |
|
Diluted EPS
|
-0.49 | -1.16 | -3.57 | -0.72 | - |
|
Weighted Average Shares
|
98.31 | 23.71 | 5.33 | 25.21 | - |
|
Diluted Weighted Avg Shares
|
98.31 | 23.71 | 5.33 | 25.21 | - |
|
Comprehensive Income
|
- | - | - | - | - |